Roche Says Alecensa Shows Increased Survival Rate for People With ALK-Positive Non-Small Cell Lung Cancer
29 May 2020 - 7:02AM
Dow Jones News
By Mauro Orru
Roche Holding AG said Friday that data from a pivotal Phase 3
study shows that Alecensa has a higher five-year survival rate than
crizotinib for people living with anaplastic lymphoma
kinase-positive non-small cell lung cancer.
The Swiss drugmaker said data showed a five-year survival rate
of 62.5% with Alecensa, compared with 45.5% for crizotinib.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
May 29, 2020 01:47 ET (05:47 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.